Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 9:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 193 matching trials from the live ClinicalTrials.gov search.
Completed Not applicable Interventional Results available

LifeBio Memory Digital Reminiscence Platform

NCT04769466
Conditions
Dementia, Cognitive Impairment
Interventions
LifeBio Memory
Other
Lead sponsor
Benjamin Rose Institute on Aging
Other
Eligibility
18 Years to 112 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Completed Not applicable Interventional Results available

Optimizing Residential Treatment Gains for Adolescents

NCT05764369
Conditions
Parenting, Adolescent - Emotional Problem, Mental Disorder in Adolescence
Interventions
Parenting Wisely Residential Treatment (PWRT), TAU
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
11 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Hypothyroidism
Interventions
Liothyronine, Sodium
Drug
Lead sponsor
Ipe, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
GRIN-related Neurodevelopmental Disorder
Interventions
Radiprodil, Placebo
Drug
Lead sponsor
GRIN Therapeutics, Inc.
Industry
Eligibility
1 Month to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
17
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 14 more
Conditions
Lung Cancer
Interventions
Evidence-based radiation dose limitation to the vertebral bone marrow
Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Nashville, Tennessee • San Antonio, Texas
Conditions
Advanced Malignant Mesothelioma, Carcinoma of the Appendix, Ovarian Sarcoma, Ovarian Stromal Cancer, Pseudomyxoma Peritonei, Recurrent Colon Cancer, Recurrent Malignant Mesothelioma, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Stage III Colon Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage IV Colon Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
HIPEC Orientation, Consultation with Survivorship Navigator, Questionnaires
Behavioral · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Systemic Lupus Erythematosus
Interventions
Triptorelin Pamoate, placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
9 Years to 21 Years · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
9
States / cities
Los Angeles, California • Chicago, Illinois • Hackensack, New Jersey + 6 more
Conditions
Major Depression
Interventions
Triiodothyronine, Placebo, Sertraline
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 60 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Uncertainty, Communication Research, Emergency Medicine
Interventions
Educational Curriculum Intervention
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania
Conditions
Breast Cancer, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, ER+ Breast Cancer, Lobular Breast Carcinoma
Interventions
Neoadjuvant endocrine therapy
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
50 Years and older · Female only
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Arthritis, Rheumatoid
Interventions
Abatacept
Drug
Lead sponsor
Arthritis Northwest PLLC
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Spokane, Washington
Terminated Phase 2 Interventional Results available

Cisplatin and Nab-paclitaxel for (N2) Defined NSCLC

NCT02276560
Conditions
Stage IIIA Non-Small Cell Lung Cancer
Interventions
Neoadjuvant Cisplatin, nab-paclitaxel, Adjuvant Cisplatin,nab-paclitaxel, Adjuvant cisplatin+pemetrexed or cisplatin+gemcitabine
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
9
States / cities
Tampa, Florida • Atlanta, Georgia • Kansas City, Kansas + 6 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Soticlestat Tablets in Healthy Adults

NCT05284760
Conditions
Healthy Volunteers
Interventions
Soticlestat
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Gastrointestinal Cancer, Colorectal Cancer, Pancreatic Cancer, Gastric Cancer, Stomach Cancer, Esophageal Cancer
Interventions
MI-Walk Intervention, Physical Activity Education Pamphlet
Behavioral
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
Ann Arbor, Michigan • Brighton, Michigan • Canton, Michigan + 2 more
Conditions
Interstitial Cystitis, Bladder Pain Syndrome
Interventions
Transvaginal botulinum toxin A (BTA) injection
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Congenital Heart Disease
Interventions
Clinical Decision support system (CDSS) for inotrope weaning
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Day to 365 Days
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Not applicable Interventional Accepts healthy volunteers

Acute Pediatric Fracture Analgesia Study

NCT00520442
Conditions
Fracture
Interventions
ibuprofen, acetamin w codeine
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
4 Years to 18 Years
Enrollment
335 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Congenital Heart Defects
Interventions
Triostat, Placebo
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
Up to 5 Months
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
3
States / cities
Los Angeles, California • Palo Alto, California • Seattle, Washington
Completed Phase 1Phase 2 Interventional Results available

Developing Oral LT3 Therapy for Heart Failure - HFrEF

NCT04112316
Conditions
Heart Failure With Reduced Ejection Fraction (HFrEF), Low T3 Syndrome
Interventions
Liothyronine, Placebo
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Quality of Life, Pediatric Cancer, Caregiver Burden
Interventions
13-week session program
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 100 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Orange, California
Conditions
Breast Cancer
Interventions
ARIMIDEX (anastrazole), NOLVADEX (tamoxifen)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
60 Years and older · Female only
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
13
States / cities
Santa Rosa, California • New Britain, Connecticut • Torrington, Connecticut + 10 more
Completed Phase 4 Interventional Results available

Low Cylinder Toric

NCT00732030
Conditions
Cataracts
Interventions
Toric IOL (SN60T3)
Device
Lead sponsor
Alcon Research
Industry
Eligibility
21 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Fort Worth, Texas
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY4268989 (MORF 057) in Healthy Participants

NCT07707375
Conditions
Healthy
Interventions
LY4268989
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Daytona Beach, Florida
Completed Phase 1Phase 2 Interventional Results available

Developing Oral LT3 Therapy for Heart Failure - HFpEF

NCT04111536
Conditions
Heart Failure With Preserved Ejection Fraction, Low Triiodothyronine Syndrome
Interventions
liothyronine, Placebo
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania